Periodic Benefit-Risk Evaluation Report (PBRER/PSUR) — GLPI-103
📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. The Periodic Benefit-Risk Evaluation Report (PBRER/PSUR) — the periodic post-approval safety and benefit-risk review.
Why it exists. After approval, ICH E2C(R2) requires sponsors to periodically re-evaluate a marketed drug's cumulative benefit-risk balance using worldwide data. It is the ongoing evidence that a drug's benefits still outweigh its risks in real use.
How it is produced here. It is a pharmacovigilance ('drug safety watch') document: it gathers and interprets the simulated safety data on the fixed schedule regulators expect once a drug enters development or the market.
Format & governing standard. —
Periodic Benefit-Risk Evaluation Report (PBRER/PSUR) — GLPI-103
| Field | Value |
|---|---|
| Document ID | PSUR-001 |
| Version | 1.0 (planned structure) |
| Status | Final (portfolio) |
| Compound | GLPI-103 (GLP-1 / Apelin [APJ] receptor dual agonist) |
| Sponsor | Virtual Biopharma Inc. |
| Standard(s) | ICH E2C(R2) (PBRER) · GVP Module VII · 21 CFR 314.80 |
| Confidentiality | Confidential |
[MOCK — deep-knowledge assumption]The PBRER is a post-authorization periodic report; GLPI-103 is pre-approval, so this document defines the structure and planned content of the first PBRER to be produced after marketing authorization, with placeholder pre-approval content. Cumulative figures trace to the clinical program (CSR-301).
Change History
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-30 | Pharmacovigilance | Initial PBRER structure / plan |
1. Introduction
This PBRER will provide a comprehensive, evaluated benefit-risk assessment of GLPI-103 at defined intervals after authorization (typically 6-monthly until 2 years post-launch, then annually/per the EU reference-date list), per ICH E2C(R2) and GVP Module VII.
2. Worldwide Marketing Authorization Status
To be populated post-authorization (countries, dates, indications, dose forms). Currently investigational [MOCK].
3. Actions Taken in the Interval for Safety Reasons
To be populated (label changes, DHPCs, restrictions). None to date.
4. Changes to Reference Safety Information
Tracks changes to the Company Core Safety Information (CCSI)/labeling.
5. Estimated Exposure and Use Patterns
Patient exposure from clinical trials (cumulative ≈1,220 subjects) plus, post-launch, estimated patient exposure from sales/prescription data, by region, formulation (IV/oral), age, and sex.
6. Data in Summary Tabulations
Cumulative and interval summary tabulations of serious adverse events (clinical trials) and, post-launch, of spontaneous and solicited reports by MedDRA SOC/PT.
7. Signal and Risk Evaluation
- Summary of safety concerns (from the RMP): important identified risks (gastrointestinal events; hypoglycaemia with secretagogues), important potential risks (acute pancreatitis; thyroid C-cell tumours/MTC; cardiovascular/heart-rate), and missing information (pregnancy/lactation; severe renal/hepatic impairment; long-term).
- New/ongoing signals: none confirmed to date; the nonclinical thyroid C-cell finding is characterised as rodent-specific (M4-2.3) and monitored as a class potential risk.
- Signal evaluation follows the Signal Management Plan (SIGNAL-001).
8. Benefit Evaluation
Confirmed efficacy: superiority over oral semaglutide on HbA1c (IV −0.68%, Oral −0.34%; CSR-301) with substantial weight reduction and high responder rates; real-world effectiveness to be added post-launch.
9. Integrated Benefit-Risk Analysis
After approval, the PBRER periodically re-asks the approval question using real-world data: given everything now known, do the benefits still outweigh the risks? It is how a drug's safety is kept under review for its whole life on the market.
The benefit-risk of GLPI-103 in adults with T2DM inadequately controlled on metformin remains favourable: clinically meaningful, robust glycaemic and weight benefit against a class-consistent, monitorable, and largely manageable risk profile (M2.5.6), with the principal gastrointestinal tolerability trade-off mitigated by titration.
10. Conclusions and Actions
No new risk-minimization measures are warranted at the current (pre-authorization) stage. Post-launch, conclusions and any label/RMP changes will be presented here, with the next data-lock point and submission timeline per the reference-date list.
Comments (0)
No comments yet. Be the first to say something!